Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles



Similar documents
Clinical Research Infrastructure at the European level: the ECRIN model. Christine Kubiak ECRIN Coordination Inserm- DRCT

Increasing Innovation in R&D - Seizing early stage external growth opportunities

Roche Position on Human Stem Cells

Join our scientific talent community

Report from the visiting commitee

IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope

Automating Cell Biology Annual general meeting, September 7, Phase Holographic Imaging

Challenges in the Regulation of Pediatric Clinical Trials

Making the most of academic drug target discoveries

Exploratory Brief on Nanomedicine or the Application of Nanotechnology in Human Healthcare

DZIF-Product Development Unit (PDU)

Euro-BioImaging European Research Infrastructure for Imaging Technologies in Biological and Biomedical Sciences

ECRIN European Clinical Research Infrastructure Network.

Overview of the EHR4CR project Electronic Health Record systems for Clinical Research

Statement for the Record for the September 25, 2008, hearing entitled, Cell Phone Use and Tumors: What the Science Says

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder

Masters Learning mode (Форма обучения)

Paediatric Rheumatology InterNational Trials Organization PRINTO

STW Open Technology Programme. H2020 Future & Emerging Technology. and. GRANTS WEEK 2015 October 9 th

SERVICE LEVEL AGREEMENT! CONFIRMATION

EBiSC the first European bank for induced pluripotent stem cells

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Standard Big Data Architecture and Infrastructure

Master of Science in Biomedical Sciences

Institut für Klinische Chemie und Laboratoriumsmedizin. In vitro Diagnostics in the Health Care System of Germany. Karl J. Lackner

1. Perception of the Bancruptcy System Perception of In-court Reorganisation... 4

Call 2014: High throughput screening of therapeutic molecules and rare diseases

HOT TOPICS IN IN HEALTH CARE REFORM

The Cell Therapy Catapult

ROADMAP ON MARINE RENEWABLE ENERGY

IT Coordination Group and ECRIN Data Centers

Drug Safety of Stem Cells and other Novel Therapeutics

Jan Duffy, Research Manager, Health Industry Insights EMEA

ECRIN General Presentation

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest

Universities in National Innovation Systems. David C. Mowery Haas School of Business, University of California - Berkeley

Therapeutic strategies for the treatment of pain

RFA-OD : NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) Kurt Marek, PhD

European Market for Computerized Physician Order Entry (CPOE) Systems. M March 2011

Case Study: Sales to Trial to Marketing Life Cycle

International Stem Cell Registry

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada

THE LINCOLN INSTITUTE OF HEALTH

Clinical research: overview in France

Corporate Presentation November, 2013

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)

A leader in the development and application of information technology to prevent and treat disease.

Curricula review for Bioengineering and Medical Informatics degree programmes in the West Balkans

A career on the science park

Ask Us About Clinical Trials

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform

Attacking the Biobank Bottleneck

Regulatory aspects of Energy Investment Conditions in European Countries

[NUGENESIS SAMPLE MANAGEMENT ] AMPLE IMPROVING LAB EFFICIENCY, ANAGEMENT ACCELERATING BUSINESS DECISIONS. bigstock.com $69

A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field

The Swedish Drug Development Pipeline June A survey conducted by:

Movember Clinical Trial Award (CTA)

Università Vita-Salute San Raffaele. Prof. Lorenzo Dagna Delegate for International Relations Milan, October 3 rd 2011

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis

Building a Collaborative Informatics Platform for Translational Research: Prof. Yike Guo Department of Computing Imperial College London

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise

Global Multiple Myeloma Epidemiology and Patient Flow Analysis

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee

MOLOGEN AG German Equity Forum 2015

Navigating England s clinical research infrastructure. How NOCRI helps simplify access to accelerate discoveries

Global Haemophilia Epidemiology and Patient Flow Analysis

MALAYSIA: THE EMERGING EDUCATION HUB

EVT Execute & EVT Innovate World-class drug discovery

Advancing research: a physician s guide to clinical trials

1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration?

This is GE Healthcare

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials

2019 Healthcare That Works for All

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective

Transcription:

ITMO Neurosciences, sciences cognitives, neurologie, psychiatrie Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Technologie pour la santé 1

NEUROSCIENCE MEDICAL CHALLENGES HIGH PREVALENCE OF BRAIN DISORDERS IN EUROPE: >27% lifetime risk for brain disorders (>127 Millions in Europe) TOTAL COST OF BRAIN DISORDERS 386 Billions Euros in 2004, i.e. 829 Euros/ European inhabitant EBC study, 2005 2

HIGH ATTRITION MAKE DRUG DEVELOPMENT IN NEUROSCIENCE A RISKY BUSINESS: ONLY 7.5% SUCCESS RATE 3

NEURATRIS: THE SOLE EUROPEAN TRANSLATIONAL RESEARCH INFRASTRUCTURE DEDICATED TO NEUROSCIENCE Biomedical Industry Basic Research University or Institutes Clinical Medicine Hospitals Bridge the gap between basic biomedical research and clinical applications for the development of innovative strategies for preventing, diagnosing and treating diseases 4

EATRIS, A COMPONENT OF ESFRI EUROPEAN ROADMAP Norway (UiO) Mol Med UK (Imperial) CV Netherlands (CTMM) Cancer,CV Spain (HUVH) Cancer France (CEA) Neurosciences Finland (FIMM) Mol med Sweden (KI) Mol med Italy (ISS) Mol med Denmark (CMI) Germany (HZI, DKFZ) Inf. Dis., cancer 5

NEURATRIS: THE CONCEPT Professionalized services covering the whole chain of translational research in Neurosciences from basic sciences (target identification) to clinical application (proof of concept, phase IIa) Single entry for all Neuratris activities Understand disease mechanisms and identify drug targets Validate drug targets and intervention strategies Predict Clinical Efficacy Predict Toxicity First-in-Man Proof-ofconcept Demonstrate Clinical Efficacy Discovery Research Pre-clinical Research & Development Clinical Phase I Clinical Phase IIa Clinical Phase IIb + III 6

NEURATRIS: A NETWORK OF INNOVATIVE CENTRES UNDER AVIESAN S UMBRELLA AGTC-Nantes AGTC Atlantic gene therapy center NeuroS pin Chemical biology infrastructure L imagerie préclinique pour les biothérapies Transfert to clinic L imagerie pour comprendre le cerveau ips cells colony Institut des cellules souches Institut du Cerveau et de la Moelle 7

NEURATRIS ADDED-VALUE SIMPLIFICATION: Single entry point for Neuratris users (academia, SMEs, Pharma industry) INNOVATION: Network of high-level infrastructures based on scientific excellence (continuous methodological developments) EFFICIENCY: Full range of professionalized services including project management Accelerate translation from basic biomedical research discoveries into new innovative medical drug/biomarker/device Provide key preclinical and clinical facilities for the development of new diagnostic tools and preventive or therapeutic strategies 8

9

HIGH ATTRITION MAKE DRUG DEVELOPMENT IN NEUROSCIENCE A RISKY BUSINESS: ONLY 7.5% SUCCESS RATE 10

ESFRI LIFE SCIENCES INFRASTRUCTURES 2006 BBMRI-Biobank EATRIS-Translational research facilities ECRIN-Clinical trial platform ELIXIR-Data repositories Infrafrontier-Mouse archives and clinics INSTRUCT-Structural biology facilities 2008 EMBRC-Marine biology resources ERINHA-High-security labs EuroBioImaging-Imaging facilities EU-Openscreen-Chemical libraries 2010 ANAEE-Analysis and experimentation on ecosystems ISBE-Infrastructure for systems biology MIRRI-Microbial resources 11

NEURATRIS : CONTEXT Europe : Roadmap ESFRI 2006 EATRIS : Translational Medicine distributed Infrastructure 2008 2009 2010 Preparatory Phase 2011 2012 2013 2014 2015 2016 Construction & Operation Phase EATRIS French Contribution: Neuratris 2013 The National Infrastructure for translational research in Neurosciences 12

NEURATRIS: PROCESS Open call for project proposals on a continuous flow basis Unique Users: entry point - Academia - SMEs -Pharma industry - EATRIS Project categorization by Neuratris coordination & support (C&S) and project managers Scientific evaluation by the steering Committee, SAB +local ethic Relevance Innovation Medical Need Feasibility Project follow up by a project manager specialized in translational research in neurosciences under single quality management system Financial evaluation Logistic evaluation by C&S Evaluation of regulatory, legal and contractual issues Development plan analysis / set up by C&S 13

NEURATRIS: PROCESS Open call for project proposals on a continuous flow basis Unique Users: entry point - Academia - SMEs -Pharma industry - EATRIS Project follow up by a project manager specialized in translational research in neurosciences under unique quality management Project categorization by Neuratris coordination & support (C&S) and project managers Financial evaluation Logistic evaluation by C&S Evaluation of regulatory, legal and contractual issues (PI) Research projects Service oriented projects Scientific evaluation by the steering Committee, SAB +local ethics Relevance Innovation Medical Need Feasibility Development plan analysis / set up by C&S 14